Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
| Revenue (Most Recent Fiscal Year) | $434.43M |
| Net Income (Most Recent Fiscal Year) | $275.19M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 63.44 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 14.19 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.28 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.53 |
| Pre-Tax Margin (Trailing 12 Months) | 27.47% |
| Net Margin (Trailing 12 Months) | 27.04% |
| Return on Equity (Trailing 12 Months) | 9.22% |
| Return on Assets (Trailing 12 Months) | 8.31% |
| Current Ratio (Most Recent Fiscal Quarter) | 17.25 |
| Quick Ratio (Most Recent Fiscal Quarter) | 17.26 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.12 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.19 |
| Earnings per Share (Most Recent Fiscal Year) | $4.23 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 61.98M |
| Free Float | 58.95M |
| Market Capitalization | $2.95B |
| Average Volume (Last 20 Days) | 0.75M |
| Beta (Past 60 Months) | 2.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.63% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |